Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
BACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: ) of acquired isolates was measured with the TZM-bl assay. RESULTS: <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipi...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Ver en el sistema de origen Enlace permanente (DOI o Handle) Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508873447145472 |
|---|---|
| author | Lawrence Corey Peter B. Gilbert Michal Juraska David C. Montefiori Lynn Morris Shelly Karuna Srilatha Edupuganti Nyaradzo Mgodi Allan C. deCamp Erika Rudnicki Yunda Huang Pedro Gonzáles Robinson Cabello Catherine Orrell Javier R. Lama Fatima Laher Erica Lazarus Jorge Sánchez Ian Frank Juan Hinojosa Magdalena E. Sobieszczyk Kyle Marshall Pamela Mukwekwerere Joseph Makhema Lindsey R. Baden James I. Mullins Carolyn Williamson John Hural M. Juliana McElrath Carter Bentley Simbarashe Takuva Margarita M. Gomez Lorenzo David Burns Nicole Espy April K. Randhawa Nidhi Kochar Estelle Piwowar‐Manning Deborah Donnell Nirupama Sista P. Andrew James G. Kublin Glenda Gray Julie E. Ledgerwood John R. Mascola Myron S. Cohen |
| author_browse | Allan C. deCamp April K. Randhawa Carolyn Williamson Carter Bentley Catherine Orrell David Burns David C. Montefiori Deborah Donnell Erica Lazarus Erika Rudnicki Estelle Piwowar‐Manning Fatima Laher Glenda Gray Ian Frank James G. Kublin James I. Mullins Javier R. Lama John Hural John R. Mascola Jorge Sánchez Joseph Makhema Juan Hinojosa Julie E. Ledgerwood Kyle Marshall Lawrence Corey Lindsey R. Baden Lynn Morris M. Juliana McElrath Magdalena E. Sobieszczyk Margarita M. Gomez Lorenzo Michal Juraska Myron S. Cohen Nicole Espy Nidhi Kochar Nirupama Sista Nyaradzo Mgodi P. Andrew Pamela Mukwekwerere Pedro Gonzáles Peter B. Gilbert Robinson Cabello Shelly Karuna Simbarashe Takuva Srilatha Edupuganti Yunda Huang |
| author_facet | Lawrence Corey Peter B. Gilbert Michal Juraska David C. Montefiori Lynn Morris Shelly Karuna Srilatha Edupuganti Nyaradzo Mgodi Allan C. deCamp Erika Rudnicki Yunda Huang Pedro Gonzáles Robinson Cabello Catherine Orrell Javier R. Lama Fatima Laher Erica Lazarus Jorge Sánchez Ian Frank Juan Hinojosa Magdalena E. Sobieszczyk Kyle Marshall Pamela Mukwekwerere Joseph Makhema Lindsey R. Baden James I. Mullins Carolyn Williamson John Hural M. Juliana McElrath Carter Bentley Simbarashe Takuva Margarita M. Gomez Lorenzo David Burns Nicole Espy April K. Randhawa Nidhi Kochar Estelle Piwowar‐Manning Deborah Donnell Nirupama Sista P. Andrew James G. Kublin Glenda Gray Julie E. Ledgerwood John R. Mascola Myron S. Cohen |
| author_sort | Lawrence Corey |
| collection | Producción científica |
| description | BACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: ) of acquired isolates was measured with the TZM-bl assay. RESULTS: <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9). The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONS: VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective. (Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials.gov numbers, NCT02716675 and NCT02568215.). |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/1763 |
| institution | UPeU |
| language | English |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/17632026-10-30T16:16:43ZTwo Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence CoreyPeter B. GilbertMichal JuraskaDavid C. MontefioriLynn MorrisShelly KarunaSrilatha EdupugantiNyaradzo MgodiAllan C. deCampErika RudnickiYunda HuangPedro GonzálesRobinson CabelloCatherine OrrellJavier R. LamaFatima LaherErica LazarusJorge SánchezIan FrankJuan HinojosaMagdalena E. SobieszczykKyle MarshallPamela MukwekwerereJoseph MakhemaLindsey R. BadenJames I. MullinsCarolyn WilliamsonJohn HuralM. Juliana McElrathCarter BentleySimbarashe TakuvaMargarita M. Gomez LorenzoDavid BurnsNicole EspyApril K. RandhawaNidhi KocharEstelle Piwowar‐ManningDeborah DonnellNirupama SistaP. AndrewJames G. KublinGlenda GrayJulie E. LedgerwoodJohn R. MascolaMyron S. CohenHuman immunodeficiency virus (HIV)AntibodyVirologyNeutralizing antibodyVirusImmunologyMedicineHuman immunodeficiency virus (HIV)AntibodyVirologyNeutralizing antibodyVirusImmunologyMedicineProof of Concept StudyProof of Concept StudyProof of Concept StudyProof of Concept StudyProof of Concept StudyBroadly Neutralizing Antibodies adverse effectsBroadly Neutralizing Antibodies adverse effectsBroadly Neutralizing Antibodies adverse effectsBroadly Neutralizing Antibodies adverse effectsBroadly Neutralizing Antibodies adverse effectsBroadly Neutralizing Antibodies therapeutic useBroadly Neutralizing Antibodies therapeutic useBroadly Neutralizing Antibodies therapeutic useBroadly Neutralizing Antibodies therapeutic useBroadly Neutralizing Antibodies therapeutic useAdolescentAdolescentAdolescentAdolescentAdolescentAdultAdultAdultAdultAdultAmericas epidemiologyAmericas epidemiologyAmericas epidemiologyAmericas epidemiologyAmericas epidemiologyAntibodies, Monoclonal adverse effectsAntibodies, Monoclonal adverse effectsAntibodies, Monoclonal adverse effectsAntibodies, Monoclonal adverse effectsAntibodies, Monoclonal adverse effectsAntibodies, Monoclonal therapeutic useAntibodies, Monoclonal therapeutic useAntibodies, Monoclonal therapeutic useAntibodies, Monoclonal therapeutic useAntibodies, Monoclonal therapeutic useDouble-Blind MethodDouble-Blind MethodDouble-Blind MethodDouble-Blind MethodDouble-Blind MethodEurope epidemiologyEurope epidemiologyEurope epidemiologyEurope epidemiologyEurope epidemiologyFemaleFemaleFemaleFemaleFemaleHumansHumansHumansHumansHumansMaleMaleMaleMaleMaleHIV Antibodies adverse effectsHIV Antibodies adverse effectsHIV Antibodies adverse effectsHIV Antibodies adverse effectsHIV Antibodies adverse effectsHIV Antibodies therapeutic useHIV Antibodies therapeutic useHIV Antibodies therapeutic useHIV Antibodies therapeutic useHIV Antibodies therapeutic useHIV-1 drug effectsHIV-1 drug effectsHIV-1 drug effectsHIV-1 drug effectsHIV-1 drug effectsHIV Infections epidemiologyHIV Infections epidemiologyHIV Infections epidemiologyHIV Infections epidemiologyHIV Infections epidemiologyHIV Infections prevention & controlHIV Infections prevention & controlHIV Infections prevention & controlHIV Infections prevention & controlHIV Infections prevention & controlIncidenceIncidenceIncidenceIncidenceIncidenceAfrica South of the Sahara epidemiologyAfrica South of the Sahara epidemiologyAfrica South of the Sahara epidemiologyAfrica South of the Sahara epidemiologyAfrica South of the Sahara epidemiologyYoung AdultYoung AdultYoung AdultYoung AdultYoung AdultLife Sciences Immunology and Microbiology Virology HIV Research and TreatmentHealth Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatmentLife Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology Biological Research and Disease StudiesBACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: ) of acquired isolates was measured with the TZM-bl assay. RESULTS: <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9). The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONS: VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective. (Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials.gov numbers, NCT02716675 and NCT02568215.).Articlehttps://pubmed.ncbi.nlm.nih.gov/33730454https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031738?articleTools=truehttps://doi.org/10.1056/nejmoa203173810.1056/nejmoa2031738https://hdl.handle.net/20.500.15037/1763W3138945586enNew England Journal of Medicine0028-47931533-44062021-03-172026-06-13T14:21:46Z2026-06-13T14:21:46Z |
| spellingShingle | Human immunodeficiency virus (HIV) Antibody Virology Neutralizing antibody Virus Immunology Medicine Human immunodeficiency virus (HIV) Antibody Virology Neutralizing antibody Virus Immunology Medicine Proof of Concept Study Proof of Concept Study Proof of Concept Study Proof of Concept Study Proof of Concept Study Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Adolescent Adolescent Adolescent Adolescent Adolescent Adult Adult Adult Adult Adult Americas epidemiology Americas epidemiology Americas epidemiology Americas epidemiology Americas epidemiology Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Double-Blind Method Double-Blind Method Double-Blind Method Double-Blind Method Double-Blind Method Europe epidemiology Europe epidemiology Europe epidemiology Europe epidemiology Europe epidemiology Female Female Female Female Female Humans Humans Humans Humans Humans Male Male Male Male Male HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control Incidence Incidence Incidence Incidence Incidence Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Young Adult Young Adult Young Adult Young Adult Young Adult Life Sciences Immunology and Microbiology Virology HIV Research and Treatment Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology Biological Research and Disease Studies Lawrence Corey Peter B. Gilbert Michal Juraska David C. Montefiori Lynn Morris Shelly Karuna Srilatha Edupuganti Nyaradzo Mgodi Allan C. deCamp Erika Rudnicki Yunda Huang Pedro Gonzáles Robinson Cabello Catherine Orrell Javier R. Lama Fatima Laher Erica Lazarus Jorge Sánchez Ian Frank Juan Hinojosa Magdalena E. Sobieszczyk Kyle Marshall Pamela Mukwekwerere Joseph Makhema Lindsey R. Baden James I. Mullins Carolyn Williamson John Hural M. Juliana McElrath Carter Bentley Simbarashe Takuva Margarita M. Gomez Lorenzo David Burns Nicole Espy April K. Randhawa Nidhi Kochar Estelle Piwowar‐Manning Deborah Donnell Nirupama Sista P. Andrew James G. Kublin Glenda Gray Julie E. Ledgerwood John R. Mascola Myron S. Cohen Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition |
| title | Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition |
| title_full | Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition |
| title_fullStr | Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition |
| title_full_unstemmed | Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition |
| title_short | Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition |
| title_sort | two randomized trials of neutralizing antibodies to prevent hiv 1 acquisition |
| topic | Human immunodeficiency virus (HIV) Antibody Virology Neutralizing antibody Virus Immunology Medicine Human immunodeficiency virus (HIV) Antibody Virology Neutralizing antibody Virus Immunology Medicine Proof of Concept Study Proof of Concept Study Proof of Concept Study Proof of Concept Study Proof of Concept Study Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Adolescent Adolescent Adolescent Adolescent Adolescent Adult Adult Adult Adult Adult Americas epidemiology Americas epidemiology Americas epidemiology Americas epidemiology Americas epidemiology Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Double-Blind Method Double-Blind Method Double-Blind Method Double-Blind Method Double-Blind Method Europe epidemiology Europe epidemiology Europe epidemiology Europe epidemiology Europe epidemiology Female Female Female Female Female Humans Humans Humans Humans Humans Male Male Male Male Male HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control Incidence Incidence Incidence Incidence Incidence Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Young Adult Young Adult Young Adult Young Adult Young Adult Life Sciences Immunology and Microbiology Virology HIV Research and Treatment Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology Biological Research and Disease Studies |
| topic_facet | Human immunodeficiency virus (HIV) Antibody Virology Neutralizing antibody Virus Immunology Medicine Human immunodeficiency virus (HIV) Antibody Virology Neutralizing antibody Virus Immunology Medicine Proof of Concept Study Proof of Concept Study Proof of Concept Study Proof of Concept Study Proof of Concept Study Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies adverse effects Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Broadly Neutralizing Antibodies therapeutic use Adolescent Adolescent Adolescent Adolescent Adolescent Adult Adult Adult Adult Adult Americas epidemiology Americas epidemiology Americas epidemiology Americas epidemiology Americas epidemiology Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal adverse effects Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Antibodies, Monoclonal therapeutic use Double-Blind Method Double-Blind Method Double-Blind Method Double-Blind Method Double-Blind Method Europe epidemiology Europe epidemiology Europe epidemiology Europe epidemiology Europe epidemiology Female Female Female Female Female Humans Humans Humans Humans Humans Male Male Male Male Male HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies adverse effects HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV Antibodies therapeutic use HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV-1 drug effects HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections epidemiology HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control HIV Infections prevention & control Incidence Incidence Incidence Incidence Incidence Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Africa South of the Sahara epidemiology Young Adult Young Adult Young Adult Young Adult Young Adult Life Sciences Immunology and Microbiology Virology HIV Research and Treatment Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology Biological Research and Disease Studies |
| url | https://pubmed.ncbi.nlm.nih.gov/33730454 https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031738?articleTools=true https://doi.org/10.1056/nejmoa2031738 https://hdl.handle.net/20.500.15037/1763 |
| work_keys_str_mv | AT lawrencecorey tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT peterbgilbert tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT michaljuraska tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT davidcmontefiori tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT lynnmorris tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT shellykaruna tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT srilathaedupuganti tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT nyaradzomgodi tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT allancdecamp tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT erikarudnicki tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT yundahuang tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT pedrogonzales tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT robinsoncabello tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT catherineorrell tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT javierrlama tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT fatimalaher tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT ericalazarus tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT jorgesanchez tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT ianfrank tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT juanhinojosa tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT magdalenaesobieszczyk tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT kylemarshall tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT pamelamukwekwerere tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT josephmakhema tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT lindseyrbaden tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT jamesimullins tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT carolynwilliamson tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT johnhural tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT mjulianamcelrath tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT carterbentley tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT simbarashetakuva tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT margaritamgomezlorenzo tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT davidburns tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT nicoleespy tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT aprilkrandhawa tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT nidhikochar tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT estellepiwowarmanning tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT deborahdonnell tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT nirupamasista tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT pandrew tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT jamesgkublin tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT glendagray tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT julieeledgerwood tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT johnrmascola tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition AT myronscohen tworandomizedtrialsofneutralizingantibodiestopreventhiv1acquisition |